{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:25Z","timestamp":1787440945864,"version":"build-2736575974"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA276152"],"award-info":[{"award-number":["R01CA276152"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["R01AI140405"],"award-info":[{"award-number":["R01AI140405"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119510","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:56:12Z","timestamp":1779717372000},"page":"119510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel microtubule inhibitor modulates the myeloid PD-L1 expression, restores T cell effector function, and promotes apoptosis for effective suppression of colorectal cancer"],"prefix":"10.1016","volume":"200","author":[{"given":"Md Abdullah Al","family":"Mamun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Rakib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-1668","authenticated-orcid":false,"given":"Mousumi","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-4474","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7048-4325","authenticated-orcid":false,"given":"Udai P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119510_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrclinonc.2013.12","article-title":"Colorectal cancer screening\u2014optimizing current strategies and new directions","volume":"10","author":"Kuipers","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119510_bib2","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, K.D. Miller, S.A. Fedewa, D.J. Ahnen, R.G. Meester, A. Barzi, Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians. 2017;67:177-193.","DOI":"10.3322\/caac.21395"},{"key":"10.1016\/j.biopha.2026.119510_bib3","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, N.S. Wagle, A. Cercek, R.A. Smith, A. JemalColorectal cancer statistics, 2023. CA: a cancer journal for clinicians. 2023;73:233-254.","DOI":"10.3322\/caac.21772"},{"key":"10.1016\/j.biopha.2026.119510_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","article-title":"Peyrin\u2013Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies","volume":"10","author":"Jess","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119510_bib5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/sj.bjc.6602783","article-title":"Side effects during chemotherapy predict tumour response in advanced colorectal cancer","volume":"93","author":"Schuell","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119510_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.10614","article-title":"Minocycline and doxycycline are not beneficial in a model of Huntington's disease","volume":"54","author":"Smith","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2026.119510_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119510_bib8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1189\/jlb.1107773","article-title":"The essential role of the in situ immune reaction in human colorectal cancer","volume":"84","author":"Pag\u00e8s","year":"2008","journal-title":"J. Leucoc. Biol."},{"key":"10.1016\/j.biopha.2026.119510_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2021.12.022","article-title":"Innate tumor killers in colorectal cancer","volume":"527","author":"Zhong","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119510_bib10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119510_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prp.2009.10.001","article-title":"Cancer immunoediting and \u201cspontaneous\u201d tumor regression","volume":"206","author":"Sengupta","year":"2010","journal-title":"Pathol. -Res. Pract."},{"key":"10.1016\/j.biopha.2026.119510_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.biopha.2026.119510_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41580-018-0009-y","article-title":"Microtubule dynamics: an interplay of biochemistry and mechanics","volume":"19","author":"Brouhard","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2026.119510_bib14","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1242\/dev.153171","article-title":"Microtubule organization, dynamics and functions in differentiated cells","volume":"144","author":"Muroyama","year":"2017","journal-title":"Development"},{"key":"10.1016\/j.biopha.2026.119510_bib15","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","article-title":"Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance","volume":"8","author":"Perez","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119510_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/ijo.2023.5567","article-title":"Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein","volume":"63","author":"Tian","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2026.119510_bib17","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s11095-012-0814-5","article-title":"Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer","volume":"29","author":"Li","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2026.119510_bib18","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1021\/acs.jmedchem.8b00827","article-title":"Structural modification of the 3, 4, 5-trimethoxyphenyl moiety in the tubulin inhibitor VERU-111 leads to improved antiproliferative activities","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119510_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.canlet.2019.11.035","article-title":"VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway","volume":"470","author":"Kashyap","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119510_bib20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/1535-7163.MCT-19-0536","article-title":"An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance","volume":"19","author":"Deng","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119510_bib21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2020.09.004","article-title":"Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer","volume":"495","author":"Mahmud","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119510_bib22","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.3390\/cancers14215336","article-title":"Sabizabulin, a potent orally bioavailable colchicine binding site agent, suppresses HER2+ breast cancer and metastasis","volume":"14","author":"Krutilina","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119510_bib23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.119510_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103180","article-title":"Immune system in cancer radiotherapy: resistance mechanisms and therapy perspectives","volume":"157","author":"Mortezaee","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.biopha.2026.119510_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117379","article-title":"DJ-X-013 reduces LPS-induced inflammation, modulates Th17\/myeloid-derived suppressor cells, and alters NF-\u03baB expression to ameliorate experimental colitis","volume":"179","author":"Mandal","year":"2024","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.biopha.2026.119510_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3892\/ol.2021.12886","article-title":"Association between cellular immune response and spleen weight in mice with hepatocellular carcinoma","volume":"22","author":"Jiang","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2026.119510_bib27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119510_bib28","article-title":"The role of CD8+ T-cells in colorectal cancer immunotherapy","volume":"10","author":"He","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2026.119510_bib29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2026.119510_bib30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.immuni.2012.11.012","article-title":"Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node","volume":"38","author":"Kastenm\u00fcller","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2026.119510_bib31","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/febs.15238","article-title":"NKT cells and the regulation of intestinal immunity: a two-way street","volume":"287","author":"Brailey","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2026.119510_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10585-023-10257-z","article-title":"Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade","volume":"41","author":"Wang","year":"2024","journal-title":"Clin. & Exp. Metastas-.-."},{"key":"10.1016\/j.biopha.2026.119510_bib33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119510_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3\u2014potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ccr.2011.08.012","article-title":"Tumor entrained neutrophils inhibit seeding in the premetastatic lung","volume":"20","author":"Granot","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.119510_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41423-024-01244-9","article-title":"Neutrophils in cancer: from biology to therapy","volume":"22","author":"Koenderman","year":"2025","journal-title":"Cell. & Mol. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","article-title":"Neutrophils in cancer: heterogeneous and multifaceted","volume":"22","author":"Hedrick","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867260","article-title":"The role of M1\/M2 macrophage polarization in rheumatoid arthritis synovitis","volume":"13","author":"Cutolo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib39","article-title":"The paradoxical role of IFN-\u03b3 in cancer: balancing immune activation and immune evasion","author":"Liu","year":"2025","journal-title":"Pathol. -Res. Pract."},{"key":"10.1016\/j.biopha.2026.119510_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41419-017-0140-2","article-title":"The BAX\/BAK-like protein BOK is a prognostic marker in colorectal cancer","volume":"9","author":"Carberry","year":"2018","journal-title":"Cell death & Dis."},{"key":"10.1016\/j.biopha.2026.119510_bib41","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/j.1349-7006.2000.tb00913.x","article-title":"Bax induction activates apoptotic cascade via mitochondrial cytochrome c release and Bax overexpression enhances apoptosis induced by chemotherapeutic agents in DLD-1 colon cancer cells","volume":"91","author":"Kobayashi","year":"2000","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119510_bib42","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.3390\/ijms22147371","article-title":"CXCL12-CXCR4\/CXCR7 axis in colorectal cancer: therapeutic target in preclinical and clinical studies","volume":"22","author":"Khare","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119510_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.758040","article-title":"CX3CR1 acts as a protective biomarker in the tumor microenvironment of colorectal cancer","volume":"12","author":"Yue","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s40425-019-0701-2","article-title":"Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1\/CEBPB\/NF-\u03baB signaling","volume":"7","author":"Wang","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119510_bib45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1158\/0008-5472.CAN-10-4627","article-title":"Interleukin-10 ablation promotes tumor development, growth, and metastasis","volume":"72","author":"Tanikawa","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119510_bib46","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.bbrc.2016.12.048","article-title":"Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment","volume":"482","author":"Nie","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119510_bib47","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00280-015-2903-8","article-title":"Antimitotic drugs in the treatment of cancer","volume":"76","author":"van Vuuren","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119510_bib48","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4161\/cc.5.8.2682","article-title":"Chromosomal instability, colorectal cancer and taxane resistance","volume":"5","author":"Swanton","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.biopha.2026.119510_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13046-018-1009-7","article-title":"Therapeutic efficacy of a novel \u03b2III\/\u03b2IV-tubulin inhibitor (VERU-111) in pancreatic cancer","volume":"38","author":"Kashyap","year":"2019","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119510_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.637098","article-title":"The tubulin inhibitor VERU-111 in combination with vemurafenib provides an effective treatment of vemurafenib-resistant A375 melanoma","volume":"12","author":"Cui","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119510_bib51","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.124.002298","article-title":"VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis","volume":"392","author":"Waddell","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119510_bib52","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/sj.onc.1208627","article-title":"Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype","volume":"24","author":"Eom","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119510_bib53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.cdd.4402286","article-title":"DNA damage induces two distinct modes of cell death in ovarian carcinomas","volume":"15","author":"Vakifahmetoglu","year":"2008","journal-title":"Cell Death & Differ."},{"key":"10.1016\/j.biopha.2026.119510_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/srep34653","article-title":"A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells","volume":"6","author":"Thomas","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119510_bib55","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3390\/cancers12082161","article-title":"A new inhibitor of tubulin polymerization kills multiple cancer cell types and reveals p21-mediated mechanism determining cell death after mitotic catastrophe","volume":"12","author":"Zdioruk","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119510_bib56","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/1535-7163.MCT-09-0076","article-title":"CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo","volume":"8","author":"Burns","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119510_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00439-004-1129-3","article-title":"Somatic mutations of CASP3 gene in human cancers","volume":"115","author":"Soung","year":"2004","journal-title":"Hum. Genet."},{"key":"10.1016\/j.biopha.2026.119510_bib58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0092-8674(95)90412-3","article-title":"Tumor suppressor p53 is a direct transcriptional activator of the human bax gene","volume":"80","author":"Toshiyuki","year":"1995","journal-title":"cell"},{"key":"10.1016\/j.biopha.2026.119510_bib59","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1092734","article-title":"Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis","volume":"303","author":"Chipuk","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119510_bib60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119510_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2021.105138","article-title":"Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells","volume":"73","author":"Ergul","year":"2021","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.biopha.2026.119510_bib62","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.3892\/mmr.2015.4222","article-title":"Colchicine induces apoptosis in HT-29 human colon cancer cells via the AKT and c-Jun N-terminal kinase signaling pathways","volume":"12","author":"Huang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2026.119510_bib63","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1038\/s41467-020-19933-0","article-title":"Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome","volume":"11","author":"Park","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119510_bib64","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fimmu.2015.00516","article-title":"Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy","volume":"6","author":"Kersten","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib65","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","article-title":"Immunomodulation by targeted anticancer agents","volume":"39","author":"Petroni","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.119510_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108555","article-title":"The interactions of paclitaxel with tumour microenvironment","volume":"105","author":"Yu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119510_bib67","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-022-01352-x","article-title":"Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells","volume":"15","author":"Shaw","year":"2022","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.biopha.2026.119510_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002837","article-title":"DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma","volume":"9","author":"Fitzgerald","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119510_bib69","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin\u2013driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119510_bib70","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119510_bib71","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2009.01.019","article-title":"Natural killer cells in allogeneic transplantation: effect on engraftment, graft-versus-tumor, and graft-versus-host responses","volume":"15","author":"Gill","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.biopha.2026.119510_bib72","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1089\/jir.2021.0078","article-title":"Engineering NK-92 cell by upregulating CXCR2 and IL-2 Via CRISPR-Cas9 improves its antitumor effects as cellular immunotherapy for human colon cancer","volume":"41","author":"Gao","year":"2021","journal-title":"J. Interferon & Cytokine Res."},{"key":"10.1016\/j.biopha.2026.119510_bib73","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"science"},{"key":"10.1016\/j.biopha.2026.119510_bib74","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1038\/s41467-021-22755-3","article-title":"IFN-\u03b3-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella","volume":"12","author":"Lin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119510_bib75","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00262-004-0617-6","article-title":"Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production","volume":"54","author":"Kubo","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2026.119510_bib76","doi-asserted-by":"crossref","first-page":"255","DOI":"10.18632\/oncotarget.6353","article-title":"Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition","volume":"7","author":"Di Modica","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119510_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm9409","article-title":"Human dendritic cells in cancer","volume":"7","author":"Kvedaraite","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib78","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.biopha.2026.119510_bib79","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119510_bib80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119510_bib81","first-page":"187","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib82","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.4049\/jimmunol.177.10.7303","article-title":"Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression","volume":"177","author":"Martinez","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s11658-022-00384-y","article-title":"The role of macrophage subtypes and exosomes in immunomodulation","volume":"27","author":"Gharavi","year":"2022","journal-title":"Cell. & Mol. Biol. Lett."},{"key":"10.1016\/j.biopha.2026.119510_bib84","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.hlc.2016.06.210","article-title":"Pro-inflammatory effects of colchicine on macrophages stimulated with atherogenic stimuli in vitro","volume":"25","author":"Schwarz","year":"2016","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.biopha.2026.119510_bib85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bjc.6600347","article-title":"Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes","volume":"87","author":"Tsavaris","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119510_bib86","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4049\/jimmunol.166.1.574","article-title":"CD11b\/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression","volume":"166","author":"Perera","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119510_bib87","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-018-0022-9","article-title":"The intracellular signalosome of PD-L1 in cancer cells","volume":"3","author":"Escors","year":"2018","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119510_bib88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.14377","article-title":"Macrophage targeting in cancer","volume":"1499","author":"Lopez-Yrigoyen","year":"2021","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2026.119510_bib89","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119510_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121012","article-title":"Early phago-\/endosomal escape of platinum drugs via ROS-responsive micelles for dual cancer chemo\/immunotherapy","volume":"276","author":"Shueng","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119510_bib91","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119510_bib92","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.3390\/ijms26146876","article-title":"PD-1\/PD-L1 inhibitors and chemotherapy synergy: impact on drug resistance and PD-L1 expression in breast cancer-immune cell Co-cultures","volume":"26","author":"\u00d6zen Ero\u011flu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119510_bib93","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00432-018-2642-4","article-title":"Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients","volume":"144","author":"Rojk\u00f3","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226005469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226005469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:54:46Z","timestamp":1787439286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226005469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":93,"alternative-id":["S0753332226005469"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119510","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel microtubule inhibitor modulates the myeloid PD-L1 expression, restores T cell effector function, and promotes apoptosis for effective suppression of colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119510"}}